Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, TASP0382088 showed potent selective inhibition of the ALK5 receptor, significantly reducing Smad2 phosphorylation in mouse skin following topical application.

A new antiandrogen compound was made and its detailed three-dimensional shape was described.

This review discusses various compounds targeting the androgen receptor, including recent developments in heterobifunctional degraders for prostate cancer treatment, but reports no new clinical results.

Low-dose oral minoxidil is effective and generally safe for treating hair loss in women.

This study found that a cholesterol-conjugated, cell-penetrating asiRNA targeting the androgen receptor effectively reduced hair loss and promoted hair growth in mouse models of androgenetic alopecia, suggesting potential as a novel treatment.

This study conducted a narrative literature review on androgenetic alopecia, highlighting the clinical diagnosis and management strategies, including minoxidil and 5-alpha-reductase inhibitors for men, and antiandrogens for women, along with the use of aesthetic procedures like microneedling as complementary therapies.

This study suggests that a specific region upstream of the TGF-β1 gene may play a key role in androgenetic alopecia by regulating gene expression in a cell-specific manner.

This study found that a specific amino-pyridine compound showed potent androgen receptor antagonist activity, stimulating hair growth in mice and reducing sebum production in a hamster model.

This presentation highlighted future directions in acne care, emphasizing the roles of topical and oral antibiotics, as well as skin microbiome studies. It also described how clascoterone targets androgen receptors in hair follicles and sebaceous glands to reduce sebum production.

This article discusses emerging therapies for androgenetic alopecia, highlighting the use of intradermal dutasteride, but it reports no new clinical findings.

Clofazimine may be effective for treating ashy dermatosis.

This review discusses the biology of antiandrogens and highlights available bioassay models to predict their therapeutic effects on human skin, reporting no new clinical results.

This study found that external application of DGD activates the Wnt/β-catenin signaling pathway, promoting hair follicle anagen phase entry, and is a more effective and safer treatment for androgenetic alopecia in mice compared to oral administration.

This case report discusses the use of a prostaglandin analogue for treating eyebrow loss in a patient with frontal fibrosing alopecia, but provides no new clinical results.

This study developed dissolving microneedles incorporating a new AR degrader for treating androgenetic alopecia, showing that a single application leads to superior hair regeneration compared to daily minoxidil, without systemic toxicity or androgen-related issues.

This review examines new formulations for delivering 5-α-reductase inhibitors to improve targeted drug delivery in androgenetic alopecia, but reports no new clinical results.

This review discusses current therapeutic targets and treatments for androgenic alopecia but reports no clinical results; the authors highlight the challenge of developing multi-target drugs for effective treatment.

This study used an in silico/in vitro approach to identify potential inhibitors of the enzyme SRD5A2, finding that the androgen receptor modulator MK-0773 is a moderate inhibitor, although it does not act as a covalent inhibitor like finasteride.

Cyproterone helps women with hair loss caused by genetics. More research is needed to confirm the best dose.

This study found that Finasteride significantly reduced the proliferation of acute myeloid leukemia cell lines by inhibiting androgen receptor activity.

In this study, a combined treatment of Androcur and Diane improved acne, seborrhea, hirsutism, and androgenic alopecia in women to varying degrees over two years.

In this review, researchers explored key mechanisms underlying androgenetic alopecia, revealing how hormonal, oxidative, inflammatory, and lipid dysregulation suppress hair growth pathways and suggesting new therapeutic targets such as DP2 antagonists and microbiome modulators.

This study conducted an in silico evaluation and found that berberine displayed better binding interactions with the 5α-reductase enzyme and TGF-β2 compared to minoxidil, suggesting its potential as a therapeutic agent for androgenetic alopecia.

This study reports that 4-(alkylthio)- and 4-(arylthio)-benzonitriles showed moderate sebum reduction as androgen receptor antagonists when applied topically in a validated animal model.

In this narrative review, researchers reported that oral finasteride significantly improved hair count and density in male androgenetic alopecia but had higher systemic exposure and potential side effects compared to topical formulations, which provided similar efficacy with lower systemic DHT suppression.

This study systematically reviewed androgenetic alopecia's clinical features, mechanisms, and treatments, highlighting that current drugs have limitations but emerging therapies and personalized treatment strategies could enhance efficacy and outcomes.

This study found that a 2-deoxy-D-ribose gel stimulated hair follicle growth in mice with androgenic alopecia, showing effects similar to minoxidil without additional benefits from combining the two treatments.

This study found that dutasteride was more effective than finasteride in increasing total and thick hair count and reducing thin hair count in men with AGA, with both drugs having similar side effect profiles.